Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | April 25, 2008 | ||||
Last Updated Date | December 21, 2011 | ||||
Start Date ICMJE | July 2007 | ||||
Primary Completion Date | July 2011 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Destruction of visible metastases [ Time Frame: 11-12 weeks ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00668382 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
Induction of an immune response that will destroy invisible micrometastases. [ Time Frame: 11-12 weeks ] [ Designated as safety issue: No ] | ||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection | ||||
Official Title ICMJE | Phase I Study To Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection Of Alpha-Gal Glycosphingolipids In Patients With Advanced Or Refractory Solid Tumors | ||||
Brief Summary | This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection GSL alpha-GAL in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment. |
||||
Detailed Description | Intratumoral injection of alpha gal glycolipid in experimental knockout mouse model systems incorporates into tumor cell membranes and presents these xeno-transplantation epitopes to antigen presenting cells with that particular tumor's tumor associated antigens (TAA). Thus this maneuver converts any individual tumor into an in situ tumor vaccine without the need to isolate, purify or supply TAA exogenously. The effects in these model systems demonstrate both the upregulation of cytotoxic T cells which react against the particular tumor's TAA, as well as resolution of injected primary tumor and eradication and prevention of metastatic disease at distant sites. This current study was undertaken to investigate the safety and feasibility of such an approach in humans. The major toxicity concerns are acute allergic or complement activation reactions or development of autoimmunity. The primary treatment is a single intratumoral injection of alpha gal glycolipid. The study design is a standard dose escalation design and the primary endpoint is Dose limiting toxicity at one month after injection (grade 3 or 4. Subjects are followed until death utilizing standard clinical imaging and evaluation to judge overall tumor response. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 1 | ||||
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label |
||||
Condition ICMJE | Neoplasm Metastases | ||||
Intervention ICMJE | Biological: Alpha-Gal Glycosphingolipids
Injections of intra-tumoral GSL alpha-GAL to evaluate its toxicity & efficacy
Other Name: refractory solid tumors, Alpha-Gal Glycosphingolipids |
||||
Study Arm (s) | |||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Enrollment ICMJE | 11 | ||||
Completion Date | July 2011 | ||||
Primary Completion Date | July 2011 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 75 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00668382 | ||||
Other Study ID Numbers ICMJE | UM200702 | ||||
Has Data Monitoring Committee | Yes | ||||
Responsible Party | Giles Whalen, University of Massachusetts, Worcester | ||||
Study Sponsor ICMJE | University of Massachusetts, Worcester | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | University of Massachusetts, Worcester | ||||
Verification Date | August 2011 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |